Here's What Key Metrics Tell Us About Kenvue (KVUE) Q3 Earnings
For the quarter ended September 2024, Kenvue (KVUE) reported revenue of $3.9 billion, down 0.4% over the same period last year. EPS came in at $0.28, compared to $0.31 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.92 billion, representing a surprise of -0.56%. The company delivered an EPS surprise of +3.70%, with the consensus EPS estimate being $0.27.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Kenvue performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Self Care: $1.63 billion compared to the $1.61 billion average estimate based on three analysts. The reported number represents a change of +0.7% year over year. Net Sales- Essential Health: $1.20 billion versus the three-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +1.6%. Net Sales- Skin Health and Beauty: $1.07 billion compared to the $1.09 billion average estimate based on three analysts. The reported number represents a change of -4.2% year over year. Adjusted Operating Income- Self Care: $557 million versus the two-analyst average estimate of $566.11 million. Adjusted Operating Income- Essential Health: $291 million versus the two-analyst average estimate of $150.95 million. Adjusted Operating Income- Skin Health and Beauty: $191 million versus the two-analyst average estimate of $184.07 million. View all Key Company Metrics for Kenvue here>>>Shares of Kenvue have returned +4.5% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kenvue Inc. (KVUE): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Quelle: Zacks
Nachrichten zu Kenvue
Analysen zu Kenvue
Keine Analysen gefunden.